159 related articles for article (PubMed ID: 32956761)
1. Extracellular proteolysis in glioblastoma progression and therapeutics.
Quesnel A; Karagiannis GS; Filippou PS
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188428. PubMed ID: 32956761
[TBL] [Abstract][Full Text] [Related]
2. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.
Bougnaud S; Golebiewska A; Oudin A; Keunen O; Harter PN; Mäder L; Azuaje F; Fritah S; Stieber D; Kaoma T; Vallar L; Brons NH; Daubon T; Miletic H; Sundstrøm T; Herold-Mende C; Mittelbronn M; Bjerkvig R; Niclou SP
Oncotarget; 2016 May; 7(22):31955-71. PubMed ID: 27049916
[TBL] [Abstract][Full Text] [Related]
3. Role of extracellular matrix and microenvironment in regulation of tumor growth and LAR-mediated invasion in glioblastoma.
Kim Y; Kang H; Powathil G; Kim H; Trucu D; Lee W; Lawler S; Chaplain M
PLoS One; 2018; 13(10):e0204865. PubMed ID: 30286133
[TBL] [Abstract][Full Text] [Related]
4. Role of extracellular vesicles in glioma progression.
Quezada C; Torres Á; Niechi I; Uribe D; Contreras-Duarte S; Toledo F; San Martín R; Gutiérrez J; Sobrevia L
Mol Aspects Med; 2018 Apr; 60():38-51. PubMed ID: 29222067
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy.
Dasram MH; Naidoo P; Walker RB; Khamanga SM
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338649
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments.
Perrin SL; Samuel MS; Koszyca B; Brown MP; Ebert LM; Oksdath M; Gomez GA
Biochem Soc Trans; 2019 Apr; 47(2):625-638. PubMed ID: 30902924
[TBL] [Abstract][Full Text] [Related]
7. Expression pattern of invasion-related molecules in the peritumoral brain.
Klekner Á; Hutóczki G; Virga J; Reményi-Puskár J; Tóth J; Scholtz B; Csősz É; Kalló G; Steiner L; Hortobágyi T; Bognár L
Clin Neurol Neurosurg; 2015 Dec; 139():138-43. PubMed ID: 26451999
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells.
Bischof J; Westhoff MA; Wagner JE; Halatsch ME; Trentmann S; Knippschild U; Wirtz CR; Burster T
Tumour Biol; 2017 Mar; 39(3):1010428317692227. PubMed ID: 28347245
[TBL] [Abstract][Full Text] [Related]
9. Lysosomal enzymes, cathepsins in brain tumour invasion.
Levicar N; Strojnik T; Kos J; Dewey RA; Pilkington GJ; Lah TT
J Neurooncol; 2002 May; 58(1):21-32. PubMed ID: 12160137
[TBL] [Abstract][Full Text] [Related]
10. The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour.
Smith SJ; Diksin M; Chhaya S; Sairam S; Estevez-Cebrero MA; Rahman R
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156557
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma extracellular vesicles induce the tumour-promoting transformation of neural stem cells.
Wang J; Liu J; Sun G; Meng H; Wang J; Guan Y; Yin Y; Zhao Z; Dong X; Yin S; Li H; Cheng Y; Wu H; Wu A; Yu X; Chen L
Cancer Lett; 2019 Dec; 466():1-12. PubMed ID: 31521694
[TBL] [Abstract][Full Text] [Related]
12. DSE promotes aggressive glioma cell phenotypes by enhancing HB-EGF/ErbB signaling.
Liao WC; Liao CK; Tsai YH; Tseng TJ; Chuang LC; Lan CT; Chang HM; Liu CH
PLoS One; 2018; 13(6):e0198364. PubMed ID: 29864158
[TBL] [Abstract][Full Text] [Related]
13. The landscape of the mesenchymal signature in brain tumours.
Behnan J; Finocchiaro G; Hanna G
Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
[TBL] [Abstract][Full Text] [Related]
14. Chondroitin Sulphate Proteoglycans in the Tumour Microenvironment.
Mellai M; Casalone C; Corona C; Crociara P; Favole A; Cassoni P; Schiffer D; Boldorini R
Adv Exp Med Biol; 2020; 1272():73-92. PubMed ID: 32845503
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma.
Kazanskaya GM; Tsidulko AY; Volkov AM; Kiselev RS; Suhovskih AV; Kobozev VV; Gaytan AS; Aidagulova SV; Krivoshapkin AL; Grigorieva EV
Histochem Cell Biol; 2018 Mar; 149(3):235-244. PubMed ID: 29322326
[TBL] [Abstract][Full Text] [Related]
16. Astrocyte immunometabolic regulation of the tumour microenvironment drives glioblastoma pathogenicity.
Perelroizen R; Philosof B; Budick-Harmelin N; Chernobylsky T; Ron A; Katzir R; Shimon D; Tessler A; Adir O; Gaoni-Yogev A; Meyer T; Krivitsky A; Shidlovsky N; Madi A; Ruppin E; Mayo L
Brain; 2022 Sep; 145(9):3288-3307. PubMed ID: 35899587
[TBL] [Abstract][Full Text] [Related]
17. The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors.
Yamamoto M; Ueno Y; Hayashi S; Fukushima T
Anticancer Res; 2002; 22(6C):4265-8. PubMed ID: 12553067
[TBL] [Abstract][Full Text] [Related]
18. Colon tumour secretopeptidome: insights into endogenous proteolytic cleavage events in the colon tumour microenvironment.
Greening DW; Kapp EA; Ji H; Speed TP; Simpson RJ
Biochim Biophys Acta; 2013 Nov; 1834(11):2396-407. PubMed ID: 23684732
[TBL] [Abstract][Full Text] [Related]
19. PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways.
Mu N; Gu J; Liu N; Xue X; Shu Z; Zhang K; Huang T; Chu C; Zhang W; Gong L; Zhao H; Jia B; Gao D; Shang L; Zhang W; Guo Q
Theranostics; 2018; 8(6):1527-1539. PubMed ID: 29556339
[No Abstract] [Full Text] [Related]
20. The emergent role of exosomes in glioma.
Gourlay J; Morokoff AP; Luwor RB; Zhu HJ; Kaye AH; Stylli SS
J Clin Neurosci; 2017 Jan; 35():13-23. PubMed ID: 27771233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
